Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further gains challenging. Meanwhile, competitor Novo Nordisk faces sales declines and pricing pressures. Investors are now focusing on potential acquisitions upstream in biotech, with Viking Therapeutics, Scholar Rock, and Verve Therapeutics emerging as attractive targets due to their innovative therapies and strategic fits with Lilly and Novo. These smaller companies could be key to future growth in the competitive GLP-1 market.
Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 fiscal 2026, driven by its Zepbound and Mounjaro products, which will soon be covered by Medicare. The company posted non-GAAP earnings per share of $8.55, a 156% jump fr...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
